2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?

2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?

Modern use of post-operative radioactive iodine (RAI) treatment for differentiated thyroid cancer (DTC) should be implemented in line with patient s’ risk stratification. Although beneficial effects of radioiodine are undisputed in high -risk patients, controversy remains in intermediate-risk and so...

Full description

Bibliographic Details
Main Authors:	Furio Pacini, Dagmar Fuhrer, Rossella Elisei, Daria Handkiewicz-Junak, Sophie Leboulleux, Markus Luster, Martin Schlumberger, Johannes W Smit
Format:	Article
Language:	English
Published:	Bioscientifica 2023-01-01
Series:	European Thyroid Journal
Subjects:	differentiated thyroid cancer radioiodine treatment indications
Online Access:	https://etj.bioscientifica.com/view/journals/etj/11/1/ETJ-21-0046.xml

Similar Items

Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer – a prospective comparison of long-term outcomes
by: Aleksandra Kukulska, et al.
Published: (2020-08-01)

Pros and cons of an aggressive initial treatment with surgery and radioiodine treatment in minimally invasive follicular thyroid carcinoma
by: Elisa Minaldi, et al.
Published: (2023-01-01)

Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice
by: Jaume Capdevila, et al.
Published: (2023-08-01)

CRITERIA OF WELL-DIFFERENTIATED THYROID CARCINOMA RESISTANCE TO RADIOIODINE THERAPY
by: P. O. Rumyantsev, et al.
Published: (2015-04-01)

Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers
by: Abdul Rehman Syed, et al.
Published: (2024-05-01)

Added Value of Postoperative Radioiodine Scan for Staging and Risk Stratification in Papillary Thyroid Microcarcinoma
by: Tawika Kaewchur, et al.
Published: (2021-04-01)

Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial
by: Maaike Dotinga, et al.
Published: (2022-12-01)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
by: Urbano Anido Herranz
Published: (2022-10-01)

Guidelines for radioiodine therapy in differentiated thyroid cancer and post-therapeutic follow-up
by: A. Yu. Shurinov, et al.
Published: (2024-06-01)

A Novel Reagent for Radioiodine Labeling of New Chemical Entities (NCEs) and Biomolecules
by: Krishan Kumar, et al.
Published: (2021-07-01)

Occurrence of symptomatic meningioma as a second neoplasm in patients with differentiated thyroid cancer treated with radioiodine
by: Nishikant Avinash Damle, et al.
Published: (2012-01-01)

Uptake and effect of radioiodine exposure on SKBR-3 cell lines
by: Miftah Irramah, et al.
Published: (2019-12-01)

Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine‐refractory differentiated thyroid carcinomas
by: Genpeng Li, et al.
Published: (2018-11-01)

Radioiodine treatment in female survivors of pediatric differentiated thyroid carcinoma does not affect future pregnancy rates
by: Marise Codeco de Andrade Barreto, et al.
Published: (2024-10-01)

Sudden Development of Subcutaneous Nodules Shortly after Radioiodine Treatment for Thyroid Cancer Caused by Self-Limiting Sarcoidosis
by: Wael Zaher, et al.
Published: (2020-05-01)

Concomitant lithium increases radioiodine uptake and absorbed doses per administered activity in graves’ disease: comparison of conventional versus lithium-augmented radioiodine therapy
by: Fadi Khreish, et al.
Published: (2024-04-01)

Radiation Exposure Levels in Relatives of Patients after Radioiodine Therapy
by: Bererhi H, et al.
Published: (2000-10-01)

Personalized Dosimetry in the Context of Radioiodine Therapy for Differentiated Thyroid Cancer
by: Massimiliano Pacilio, et al.
Published: (2022-07-01)

Performance tests of a portable thyroid radioiodine meter
by: Zeshu Li, et al.
Published: (2024-03-01)

A rare case of laryngotracheal chondrosarcoma in a patient with past history of radioiodine therapy for thyroid cancer
by: Gholamreza Mohajeri, et al.
Published: (2013-01-01)

Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma
by: S.M. Coelho, et al.
Published: (2011-01-01)

A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer
by: Chao Meng, et al.
Published: (2023-02-01)

Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial
by: M. S. Brose, et al.
Published: (2018-07-01)

Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
by: Dario Tumino, et al.
Published: (2017-11-01)

Improved Patient Dosimetry at Radioiodine Therapy by Combining the ICRP Compartment Model and the EANM Pre-Therapeutic Standard Procedure for Benign Thyroid Diseases
by: Martin Andersson, et al.
Published: (2021-03-01)

Progress on Targeted Therapy of Radioiodine-refractory Differentiated Thyroid Cancer
by: TENG Lisong, et al.
Published: (2023-05-01)

An Inverse Agonist of Estrogen-Related Receptor Gamma, GSK5182, Enhances Na<sup>+</sup>/I<sup>−</sup> Symporter Function in Radioiodine-Refractory Papillary Thyroid Cancer Cells
by: Thoudam Debraj Singh, et al.
Published: (2023-02-01)

Radioiodine-induced oxidative stress in patients with differentiated thyroid carcinoma and effect of supplementation with vitamins C and E and selenium (antioxidants)
by: Pedro Weslley Rosário, et al.
Published: (2016-02-01)

Strongly Radioiodine-Positive Pancreatic Adenocarcinoma Mimicking Metastasis of Differentiated Thyroid Cancer
by: Florian Rosar, et al.
Published: (2022-08-01)

Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
by: Chae Moon Hong, et al.
Published: (2017-10-01)

Value of follow-up diagnostic radioiodine scans in differentiated thyroid cancer
by: Teresa Kraus, et al.
Published: (2024-04-01)

Development and validation of nomograms for predicting survival in differentiated thyroid cancer patients with or without radioiodine therapy
by: Bingyu Ran, et al.
Published: (2023-03-01)

In properly selected patients with differentiated thyroid cancer, antithyroglobulin antibodies decline after thyroidectomy and their sole presence should not be an indication for radioiodine ablation
by: Luis Felipe Zavala, et al.
Published: (2019-04-01)

First Strike personalized predictive radioiodine prescription for inoperable metastatic differentiated thyroid cancer
by: Yung Hsiang Kao
Published: (2023-06-01)

Simplified Assessment of Radioiodine Biokinetics for Thyroid Cancer Patients: A Practical Approach Using Continuous External Radiation Monitoring
by: Yao-Kuang Tsai, et al.
Published: (2024-05-01)

Blood Profiles in the Prediction of Radioiodine Refractory Papillary Thyroid Cancer: A Case–Control Study
by: Liu H, et al.
Published: (2023-02-01)

APOPTOSIS ROLE IN FORMING RADIOIODINE RESISTANCE IN DIFFERENTIATED THYROID CANCER
by: K.A. GARIPOV, et al.
Published: (2020-06-01)

Progress in Re-differentiating Therapy of Radioiodine-refractory Differentiated Thyroid Cancer
by: ZHANG Yaqi, et al.
Published: (2022-10-01)

Primary presentation and clinical course of pediatric and adolescent patients with differentiated thyroid carcinoma after radioiodine therapy
by: Caroline Burgard, et al.
Published: (2023-10-01)

Immobilization of Radioiodine via an Interzeolite Transformation to Iodosodalite
by: Hyejin An, et al.
Published: (2020-10-01)